Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide.
OBJECTIVE
To evaluate the frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide in elderly patients.


METHODS
This clinical interventional case series study included 144 phakic eyes that consecutively received an intravitreal injection of about 20 mg triamcinolone acetonide for diffuse diabetic macular edema (n=42 eyes), exudative age-related macular degeneration (n=98), and branch retinal vein occlusion (n=4). Mean age was 72.3-/+8.9 years. Mean follow-up was 11.0-/+6.8 months (median, 8.8 months; range, 3 to 35.5 months). Reinjections were carried out in 12 (8.3%) eyes.


RESULTS
Cataract surgery was performed in 20 (13.9%) eyes 17.4-/+9.1 months (median, 12.7 months; range, 8.0 to 35.5 months) after the first intravitreal injection. Out of the 20 eyes undergoing cataract surgery, 19 (95%) eyes had received one intravitreal injection, and 1 (5%) eye had received two previous injections.


CONCLUSIONS
In the elderly population of patients with exudative age-related macular degeneration, diffuse diabetic macular edema, or branch retinal vein occlusion, intravitreal high-dosage injection of triamcinolone acetonide leads to clinically significant cataract with eventual cataract surgery in about 15% to 20% of eyes within about 1 year after the intravitreal injection.
Department of Ophthalmology and Eye Hospital, Medical Faculty Mannheim of the Ruprecht-Karls - University Heidelberg - Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
J B
JB
Jonas
R
R
Degenring
U
U
Vossmerbauemer
B
B
Kamppeter
D000368:Aged; D000369:Aged, 80 and over; D002386:Cataract / Q000139:chemically induced*; D002387:Cataract Extraction / Q000706:statistics & numerical data*; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007908:Lens, Crystalline / Q000187:drug effects*; D008875:Middle Aged; D012164:Retinal Diseases / Q000188:drug therapy; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide